HeyJaredJake Remaly
- Indexed articles, last 90 days
- 4
- Latest publication
- Sep 17, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 13, 2026
Latest articles
More Vaccine Visits, More Distress? (opens the original)
Read excerpt
Vaccine injections not only provide crucial training for the immune system but also represent “the most common source of iatrogenic pain in childhood.” Infants can’t say which vaccine schedule they prefer, but that has not stopped clinicians and researchers from trying to understand how to make the experience less painful and stressful for them. One way doctors have sought to minimize distress for the child and optimize protection against disease is by using combination vaccine products and givi
Med Op-Ed: Robot-Approved Refills, Ominous VTEs, and More (opens the original)
Read excerpt
In this installment of Med Op-Ed: Prescription renewal systems raise liability and safety concerns, when clots may signal a catastrophic prognosis, and how writing clinical notes shapes doctors. Automated prescription renewal systems promise efficiency but raise concerns about transparency, clinical monitoring, and liability when algorithms operate without meaningful physician oversight, according to Nikhil Jaiswal and colleagues writing in JAMA Internal Medicine. “The Utah patient who selected
Med Op-Ed: Unplanned GLP-1 Pregnancies, Light Activity, More (opens the original)
Read excerpt
In this installment of Med Op-Ed: A call to study the effects of GLP-1 receptor agonists on pregnancy outcomes; the public health promise of light physical activity; and what treadmill testing reveals in asymptomatic aortic stenosis. Guidelines advise against the use of GLP-1 receptor agonists during pregnancy, but many infants may be unintentionally exposed to the medications in the first trimester — including tens of thousands of children in the UK in 2026 alone, estimated Adrian Heald, DM, BM
Study Probes Absolute Risk for ION With GLP-1 Agents (opens the original)
Read excerpt
Among adults with type 2 diabetes, GLP-1 receptor agonists (RAs) were associated with a higher incidence of ischemic optic neuropathy (ION) at 18 months than SGLT2 inhibitors and DPP-4 inhibitors, an analysis of US insurance claims data showed. The absolute risk was low, however, and limitations in the design of the study mean the results should be interpreted with caution, the researchers said. “Despite the very low absolute risk for ION, the rapidly expanding use of GLP-1 RAs in patients with
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.